Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 42 (9) , 1011-1017
- https://doi.org/10.1016/0024-3205(88)90431-6
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Interaction between substituted 1-[2-(diphenylmethoxy)ethyl] piperazines and dopamine receptorsNeuropharmacology, 1985
- Transmitter deficits in Alzheimer's diseaseNeurochemistry International, 1985
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- THA—A Review of the Literature and Its Use in Treatment of Five Overdose PatientsClinical Toxicology, 1980
- Anticholinesterase Activity of Tetrahydroaminacrine and Succinyl Choline HydrolysisNature, 1965
- Enzyme Inhibiting Action of Tetrahydroaminoacridine and its Structural FragmentsJournal of Pharmacy and Pharmacology, 1962
- Treatment of Intractable Pain with Morphine and TetrahydroaminacrineBMJ, 1961
- Inhibition of Cholinesterases by Tetrahydroaminacrin.Acta Chemica Scandinavica, 1961
- TETRAHYDROAMINACRIN AS A DECURARISING AGENTJournal of Pharmacy and Pharmacology, 1958